Intravenous injection of anti-HMGB1 mAb significantly protected against BBB disruption induced by ischemia and hemorrhage in rats [14,15,16] while simultaneously inhibiting the expression of inflammation-related molecules and the activation of microglia. Here, HMGB1 is linked to ischemia.